D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. StockNews.com assumed coverage on shares of VolitionRx in a report on Tuesday. They issued a “sell” rating for the company. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.63 on Wednesday. The company has a market capitalization of $58.38 million, a price-to-earnings ratio of -1.75 and a beta of 1.20. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The company’s 50-day moving average is $0.65 and its 200 day moving average is $0.66.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes acquired 174,764 shares of the stock in a transaction dated Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 358,266 shares of company stock worth $204,212 over the last quarter. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.